Key facts
- Stata DX’s last known valuation is $14.0M (Mar 2024).
- It has raised $6.4M; the latest was Later Stage VC ($1.9M) in Apr 2026.
- Notable investors include MassVentures, Harvard University, Incept, Iyengar Capital, Wyss Institute at Harvard University.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Stata DX
- ·The full record, as it builds
Funding rounds
No funding rounds for Stata DX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Stata DX
Developer of a disease management e-rapid technology designed to implement custom biomarker panels for at-home patient monitoring in clinical studies. The company's technology offers a low-cost, affinity-based electrochemical sensing platform that can simultaneously detect a broad range of biomarkers with high sensitivity and selectivity in complex biological fluids, specifically liquid MRI for the brain, enabling researchers to get information about the composition of a system in real-time.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2021
- Employees
- 7
- Website
- statadx.com/
- Ownership
- Privately Held (backing)
Stata DX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Stata DX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Stata DX in its N-PORT filings yet. We sweep new filings monthly.